Viridian Therapeutics, Inc. (VRDN) |
|
10.7 -0.87 (-7.52%)
|
07-02 18:41 |
|
Open: |
11.6 |
Pre. Close: |
11.57 |
|
High:
|
11.61 |
Low:
|
10.59 |
|
Volume:
|
168,141 |
Market Cap:
|
299(M) |
|
|
|
|
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.62 - 11.69 |
11.69 - 11.75 |
|
Low:
|
10.45 - 10.51 |
10.51 - 10.58 |
|
Close:
|
10.6 - 10.71 |
10.71 - 10.81 |
|
Technical analysis |
as of: 2022-07-01 4:26:07 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 13.58  One year: 14.87 |
| Support: |
Support1: 9.84 Support2: 8.18 |
| Resistance: |
Resistance1: 11.62 Resistance2: 12.73 |
| Pivot: |
10.85 |
| Moving Average: |
MA(5): 10.86 MA(20): 11.06
MA(100): 15.39 MA(250): 16.41 |
| MACD: |
MACD(12,26): -0.5  Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 53.6 %D(3): 44.3 |
| RSI: |
RSI(14): 43.4 |
| 52-week: |
High: 22 Low: 9.47 |
| Average Vol(K): |
3-Month: 345 (K) 10-Days: 693 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VRDN ] has closed above bottom band by 39.2%. Bollinger Bands are 66.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 01 Jul 2022
Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates - GuruFocus.com
Mon, 27 Jun 2022
B. Riley Comments on Viridian Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:VRDN) - Defense World
Thu, 23 Jun 2022
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer - GlobeNewswire
Tue, 21 Jun 2022
Viridian Therapeutics to Participate in June Investor Conferences - GuruFocus.com
Thu, 16 Jun 2022
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm - Business Wire
Mon, 13 Jun 2022
Financial Comparison: Viridian Therapeutics (NASDAQ:VRDN) versus Exact Sciences (NASDAQ:EXAS) - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
22 (M) |
|
% Held by Insiders
|
1.872e+007 (%) |
|
% Held by Institutions
|
3.3 (%) |
|
Shares Short
|
501 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.961e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
690.7 |
|
Return on Equity (ttm)
|
-29.8 |
|
Qtrly Rev. Growth
|
2.96e+006 |
|
Gross Profit (p.s.)
|
279.52 |
|
Sales Per Share
|
-48.69 |
|
EBITDA (p.s.)
|
-5.08679e+007 |
|
Qtrly Earnings Growth
|
-19.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-55 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.22 |
|
Price to Cash Flow
|
5.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
823450 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-11-12 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
